• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

YTHDF2是一种潜在的生物标志物,与肾透明细胞癌中的免疫浸润相关。

YTHDF2 is a Potential Biomarker and Associated with Immune Infiltration in Kidney Renal Clear Cell Carcinoma.

作者信息

Su Ganglin, Liu Tianshu, Han Xiaohong, Sun Hao, Che Wenan, Hu Kun, Xiao Junwen, Li Yanfeng, Liu Yuchen, Li Wujiao, Mei Hongbing

机构信息

Department of Urology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, China.

Shantou University Medical College, Shantou, China.

出版信息

Front Pharmacol. 2021 Aug 27;12:709548. doi: 10.3389/fphar.2021.709548. eCollection 2021.

DOI:10.3389/fphar.2021.709548
PMID:34512342
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8429956/
Abstract

Clear cell renal cell carcinoma (ccRCC or KIRC) has a high mortality rate globally. It is necessary to identify biomarkers and investigate the mechanisms those biomarkers are associated with, to improve the prognosis of patients with KIRC. N6-Methyladenosine (m6A) affects the fate of modified RNA molecules and is involved in tumor progression. Different webservers were used in our research to investigate the mRNA transcription and clinical significance of YTHDF2 in KIRC. Survival analysis revealed that patients with elevated YTHDF2 transcription had a slightly longer OS and DFS than those with low YTHDF2 expression. YTHDF2 expression was shown to be significantly associated with the abundance of immune cells such as B cells, CD8 T cells, CD4 T cells, macrophages, neutrophils, and dendritic cells. For a series of enrichment studies, we combined information on YTHDF2-binding molecules and expression-linked genes and identified the possible influence of "mRNA surveillance pathway," "RNA degradation," and "RNA transport" in the biology or pathogeny of KIRC. In addition, we identified multiple miRNA, kinase, and transcription factor targets of YTHDF2 in KIRC and constructed target networks. Overall, our findings show that YTHDF2 is a possible indicator of immune infiltration in the KIRC.

摘要

透明细胞肾细胞癌(ccRCC或KIRC)在全球范围内具有较高的死亡率。有必要识别生物标志物并研究这些生物标志物相关的机制,以改善KIRC患者的预后。N6-甲基腺苷(m6A)影响修饰RNA分子的命运,并参与肿瘤进展。我们的研究使用了不同的网络服务器来研究YTHDF2在KIRC中的mRNA转录和临床意义。生存分析显示,YTHDF2转录水平升高的患者的总生存期(OS)和无病生存期(DFS)比YTHDF2表达水平低的患者略长。结果表明,YTHDF2表达与B细胞、CD8 T细胞、CD4 T细胞、巨噬细胞、中性粒细胞和树突状细胞等免疫细胞的丰度显著相关。对于一系列富集研究,我们整合了YTHDF2结合分子和表达相关基因的信息,并确定了“mRNA监测途径”、“RNA降解”和“RNA转运”在KIRC生物学或发病机制中的可能影响。此外,我们在KIRC中鉴定了YTHDF2的多个miRNA、激酶和转录因子靶点,并构建了靶点网络。总体而言,我们的研究结果表明,YTHDF2可能是KIRC中免疫浸润的一个指标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2014/8429956/8605aa4c3569/fphar-12-709548-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2014/8429956/612caef27c9f/fphar-12-709548-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2014/8429956/7fad36148ed9/fphar-12-709548-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2014/8429956/0fd98a163506/fphar-12-709548-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2014/8429956/3431baa5f0a5/fphar-12-709548-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2014/8429956/52ec405a1604/fphar-12-709548-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2014/8429956/5ece011df99b/fphar-12-709548-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2014/8429956/481b08b3a252/fphar-12-709548-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2014/8429956/8605aa4c3569/fphar-12-709548-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2014/8429956/612caef27c9f/fphar-12-709548-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2014/8429956/7fad36148ed9/fphar-12-709548-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2014/8429956/0fd98a163506/fphar-12-709548-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2014/8429956/3431baa5f0a5/fphar-12-709548-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2014/8429956/52ec405a1604/fphar-12-709548-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2014/8429956/5ece011df99b/fphar-12-709548-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2014/8429956/481b08b3a252/fphar-12-709548-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2014/8429956/8605aa4c3569/fphar-12-709548-g008.jpg

相似文献

1
YTHDF2 is a Potential Biomarker and Associated with Immune Infiltration in Kidney Renal Clear Cell Carcinoma.YTHDF2是一种潜在的生物标志物,与肾透明细胞癌中的免疫浸润相关。
Front Pharmacol. 2021 Aug 27;12:709548. doi: 10.3389/fphar.2021.709548. eCollection 2021.
2
SOX11 as a prognostic biomarker linked to m6A modification and immune infiltration in renal clear cell carcinoma.SOX11作为一种与肾透明细胞癌中m6A修饰和免疫浸润相关的预后生物标志物。
Transl Cancer Res. 2024 Jul 31;13(7):3536-3555. doi: 10.21037/tcr-24-109. Epub 2024 Jul 15.
3
Comprehensive analysis of m6A reader YTHDF2 prognosis, immune infiltration, and related regulatory networks in hepatocellular carcinoma.肝细胞癌中m6A阅读蛋白YTHDF2的预后、免疫浸润及相关调控网络的综合分析
Heliyon. 2023 Dec 3;10(1):e23204. doi: 10.1016/j.heliyon.2023.e23204. eCollection 2024 Jan 15.
4
System analysis of in renal cell carcinoma: The expression, prognosis, gene regulation network and regulation targets.系统分析肾细胞癌中的 : 表达、预后、基因调控网络和调控靶点。
Int J Biol Markers. 2022 Mar;37(1):90-101. doi: 10.1177/17246008211063501. Epub 2021 Dec 6.
5
YTHDF2 negatively correlates with tumor immune infiltration in small cell lung cancer.YTHDF2 与小细胞肺癌中的肿瘤免疫浸润呈负相关。
J Mol Histol. 2023 Aug;54(4):365-377. doi: 10.1007/s10735-023-10129-6. Epub 2023 Jun 26.
6
Hub Long Noncoding RNAs with m6A Modification for Signatures and Prognostic Values in Kidney Renal Clear Cell Carcinoma.具有m6A修饰的Hub长链非编码RNA在肾透明细胞癌中的特征及预后价值
Front Mol Biosci. 2021 Jul 6;8:682471. doi: 10.3389/fmolb.2021.682471. eCollection 2021.
7
ACE2 Is a Prognostic Biomarker and Associated with Immune Infiltration in Kidney Renal Clear Cell Carcinoma: Implication for COVID-19.血管紧张素转换酶2是肾透明细胞癌的预后生物标志物并与免疫浸润相关:对2019冠状病毒病的启示
J Oncol. 2021 Jan 28;2021:8847307. doi: 10.1155/2021/8847307. eCollection 2021.
8
TLR3 Serves as a Prognostic Biomarker and Associates with Immune Infiltration in the Renal Clear Cell Carcinoma Microenvironment.Toll样受体3作为一种预后生物标志物,与肾透明细胞癌微环境中的免疫浸润相关。
J Oncol. 2021 Sep 6;2021:3336770. doi: 10.1155/2021/3336770. eCollection 2021.
9
Systematic Analyses of the Role of the Reader Protein of -Methyladenosine RNA Methylation, YTH Domain Family 2, in Liver Hepatocellular Carcinoma.N6-甲基腺苷RNA甲基化的阅读蛋白YTH结构域家族2在肝细胞癌中作用的系统分析
Front Mol Biosci. 2020 Dec 2;7:577460. doi: 10.3389/fmolb.2020.577460. eCollection 2020.
10
YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.YTHDF2 通过 N6-甲基腺苷依赖性方式介导肿瘤抑制因子的 mRNA 降解,从而诱导前列腺癌中 AKT 的磷酸化。
Mol Cancer. 2020 Oct 29;19(1):152. doi: 10.1186/s12943-020-01267-6.

引用本文的文献

1
Renal cell carcinoma and macrophage research: A bibliometric analysis (2004-2023).肾细胞癌与巨噬细胞研究:文献计量分析(2004 - 2023年)
Medicine (Baltimore). 2024 Dec 13;103(50):e40954. doi: 10.1097/MD.0000000000040954.
2
YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8 T cell recruitment.癌周肝细胞中的 YTHDF2 通过 CX3CL1 介导的 CD8+T 细胞募集来介导化疗诱导的抗肿瘤免疫反应。
Mol Cancer. 2024 Sep 6;23(1):186. doi: 10.1186/s12943-024-02097-6.
3
Progression of mA in the tumor microenvironment: hypoxia, immune and metabolic reprogramming.

本文引用的文献

1
The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells.RNA m6A 阅读器 YTHDF2 维持致癌基因表达,是神经胶质瘤干细胞的一个可靶向依赖性。
Cancer Discov. 2021 Feb;11(2):480-499. doi: 10.1158/2159-8290.CD-20-0331. Epub 2020 Oct 6.
2
YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation.YTHDF2 通过调控 OCT4 表达的 m6A RNA 甲基化促进肝癌干细胞表型和癌症转移。
Oncogene. 2020 Jun;39(23):4507-4518. doi: 10.1038/s41388-020-1303-7. Epub 2020 May 4.
3
Integrated analysis of the E2F transcription factors across cancer types.
肿瘤微环境中微小RNA的进展:缺氧、免疫和代谢重编程。
Cell Death Discov. 2024 Jul 20;10(1):331. doi: 10.1038/s41420-024-02092-2.
4
Role of mA modifications in immune evasion and immunotherapy.mA 修饰在免疫逃逸和免疫治疗中的作用。
Med Oncol. 2024 May 18;41(6):159. doi: 10.1007/s12032-024-02402-9.
5
RNA N-methyladenosine modifications in urological cancers: from mechanism to application.尿路上皮癌中 RNA N6-甲基腺嘌呤修饰:从机制到应用。
Nat Rev Urol. 2024 Aug;21(8):460-476. doi: 10.1038/s41585-023-00851-x. Epub 2024 Feb 12.
6
The role of RNA modification in urological cancers: mechanisms and clinical potential.RNA修饰在泌尿系统癌症中的作用:机制与临床潜力
Discov Oncol. 2023 Dec 20;14(1):235. doi: 10.1007/s12672-023-00843-8.
7
Key mA regulators mediated methylation modification pattern and immune infiltration characterization in hepatic ischemia-reperfusion injury.关键 mA 调控因子介导肝缺血再灌注损伤中的甲基化修饰模式和免疫浸润特征。
BMC Med Genomics. 2023 Dec 4;16(1):314. doi: 10.1186/s12920-023-01751-0.
8
The current landscape of m6A modification in urological cancers.尿路上皮癌中 m6A 修饰的现状。
PeerJ. 2023 Sep 7;11:e16023. doi: 10.7717/peerj.16023. eCollection 2023.
9
Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets.肿瘤微环境中的表观遗传调控:分子机制和治疗靶点。
Signal Transduct Target Ther. 2023 May 22;8(1):210. doi: 10.1038/s41392-023-01480-x.
10
Targeting RNA N6-methyladenosine to synergize with immune checkpoint therapy.靶向 RNA N6-甲基腺苷以协同免疫检查点治疗。
Mol Cancer. 2023 Feb 21;22(1):36. doi: 10.1186/s12943-023-01746-6.
跨癌症类型的 E2F 转录因子的综合分析。
Oncol Rep. 2020 Apr;43(4):1133-1146. doi: 10.3892/or.2020.7504. Epub 2020 Feb 17.
4
Circular RNA circ_0001105 Inhibits Progression and Metastasis of Osteosarcoma by Sponging miR-766 and Activating YTHDF2 Expression.环状RNA circ_0001105通过吸附miR-766和激活YTHDF2表达抑制骨肉瘤的进展和转移。
Onco Targets Ther. 2020 Feb 26;13:1723-1736. doi: 10.2147/OTT.S234668. eCollection 2020.
5
METTL3/YTHDF2 m A axis promotes tumorigenesis by degrading SETD7 and KLF4 mRNAs in bladder cancer.METTL3/YTHDF2 mA 轴通过降解膀胱癌中的 SETD7 和 KLF4 mRNA 促进肿瘤发生。
J Cell Mol Med. 2020 Apr;24(7):4092-4104. doi: 10.1111/jcmm.15063. Epub 2020 Mar 3.
6
Checkpoint inhibitor immunotherapy in kidney cancer.检查点抑制剂免疫疗法在肾癌中的应用。
Nat Rev Urol. 2020 Mar;17(3):137-150. doi: 10.1038/s41585-020-0282-3. Epub 2020 Feb 4.
7
m6A RNA methylation regulators can contribute to malignant progression and impact the prognosis of bladder cancer.m6A RNA 甲基化调控因子可促进膀胱癌的恶性进展并影响其预后。
Biosci Rep. 2019 Dec 20;39(12). doi: 10.1042/BSR20192892.
8
YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma.YTHDF2 减少可促进肝癌中的炎症和血管异常化。
Mol Cancer. 2019 Nov 18;18(1):163. doi: 10.1186/s12943-019-1082-3.
9
METTL3-mediated mA modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance.METTL3 介导的 HDGF mRNA mA 修饰促进胃癌进展并具有预后意义。
Gut. 2020 Jul;69(7):1193-1205. doi: 10.1136/gutjnl-2019-319639. Epub 2019 Oct 3.
10
METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner.METTL3 通过 m6A 依赖性方式促进pri-miR221/222 的成熟来促进膀胱癌肿瘤的增殖。
Mol Cancer. 2019 Jun 22;18(1):110. doi: 10.1186/s12943-019-1036-9.